Unlocking the Future of Oncology with Actuate Therapeutics (NASDAQ: ACTU)
Actuate Therapeutics, Inc. (NASDAQ: ACTU) is at the forefront of a transformative approach to cancer treatment, focusing on cutting-edge therapies that target aggressive tumor biology. With its proprietary drug development platform and commitment to innovation, Actuate is well-positioned to revolutionize the oncology sector and deliver long-term value for investors.
The Actuate Vision: Redefining Cancer Treatment
Actuate Therapeutics is pioneering the next generation of oncology solutions through its breakthrough research on Glycogen Synthase Kinase-3 Beta (GSK-3β) inhibitors. By targeting key pathways involved in tumor cell plasticity, Actuate is advancing promising therapies that combat chemoresistance and improve patient outcomes.
Through a robust clinical pipeline and partnerships with leading research institutions, Actuate is tackling some of the most challenging cancers, including pancreatic ductal adenocarcinoma (PDAC). With a vision rooted in scientific rigor and innovation, the company is set to redefine the standard of care in cancer treatment.
LATEST NEWS
Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer
5 Reasons Why Actuate Therapeutics (NASDAQ: ACTU) Could Be Poised For Significant Upside Potential in 2025
IDENTIFYING THE OPPORTUNITY
THIS BATTERING RAM IS READY TO BREAK THROUGH
With a float of 48M and few restricted shares, a little bit of investor interest could send this soaring!
TRADE CONFIRMATION
Ideally, we would see a strong open and sustain a volume push over 10k. We need to see it push through this local resistance trendline and maintain this longer-term support in doing so. Once we see that, we should see some nice confirmations and can ride the wave.
TARGETS
Target #1: $0.28 (+64.71%)
Target #2: $0.48 (+182.35%)
Target #3: $0.68 (+300.00%)
Support: $0.06
ACTUATE THERAPEUTICS
(NASDAQ: ACTU)
Disrupting Oncology with Targeted Therapeutics
Actuate’s innovative drug development is centered on combating epithelial to mesenchymal transition (EMT), a key driver of tumor aggression and metastasis. The company’s lead asset, elraglusib, is designed to work synergistically with chemotherapy, reversing resistance mechanisms and improving survival outcomes.
Early clinical data from the COMPASS trial and NCT05077800 indicate that elraglusib effectively converts resistant tumor cells into a more treatable state, offering a game-changing advancement in pancreatic cancer therapy. By inhibiting GSK-3β and TGFβ pathways, Actuate’s approach is addressing a fundamental weakness in conventional cancer treatments.
The company’s proprietary research suggests that patients receiving FOLFIRINOX in combination with elraglusib exhibit phenotypic shifts that enhance treatment efficacy. This ability to manipulate tumor biology represents a paradigm shift in oncology and underscores Actuate’s potential for long-term clinical and financial success.
A Strong Clinical Foundation with Global Impact
Actuate’s leadership team, composed of world-class oncologists, researchers, and biotech executives, is driving the company’s mission forward. Its scientific approach is validated by rigorous research and clinical collaborations with institutions like Massachusetts General Hospital and leading cancer centers worldwide.
Beyond pancreatic cancer, Actuate is exploring applications for its GSK-3β inhibitors across multiple cancer types, expanding its potential market footprint in the global oncology landscape. This broad applicability makes Actuate a multi-dimensional investment opportunity in the biotech space.
Separating From The Competition
With a first-mover advantage in targeted oncology, strong clinical momentum, and an increasing focus on novel cancer therapies, Actuate Therapeutics presents a compelling investment case. As the company advances its clinical trials and regulatory milestones, investors have the opportunity to gain exposure to one of the most promising biotech innovations in cancer treatment.
The future of oncology is shifting towards precision medicine and targeted therapies—and Actuate Therapeutics is leading that charge.
Introducing the Actuate Therapeutics Team
(NASDAQ: ACTU)
Daniel M. Schmitt | President & CEO
Mr. Schmitt brings over 30 years of successful industry experience in operations management, new product development, and business development, having held senior executive positions in both large pharmaceutical and small biotechnology companies, including Fujisawa, Searle / Pharmacia, and Ilex Oncology. During his career, Daniel has led and contributed to the successful development and launch of multiple pharmaceutical products, and has constructed and executed numerous high value licensing, acquisition, and development deals for biotech and pharmaceutical companies, totaling nearly $1 billion in upfront and potential milestone payments.
Andrew P. Mazar, Ph. D | COO
Dr. Mazar currently serves as Chief Operating Officer of Actuate Therapeutics. He is a translational researcher, drug development thought leader and entrepreneur that has over 30 years experience working on translational oncology and fibrosis programs at the interface of academia and industry spanning discovery through phase 3 trial design and implementation. Dr. Mazar has led pre-clinical and early clinical development for targeted oncology drugs including antibodies, peptides, antibody and peptide conjugates, and small molecules. He has also led discovery and application of mechanism-based biomarkers to drug pharmacodynamics, candidate selection and patient enrichment.
His operational expertise spans academia and industry, including academic spin outs and start-up company formation, financing, business development and partnership, and commercialization. He has also led regulatory interactions with FDA and EMA, resulting in INDs, orphan drug designations; four drugs advanced to phase 3 and numerous phase 1 & phase 2 human trials. Dr. Mazar is a recognized expert in cancer metastasis research and specifically in the urokinase plasminogen activator (uPA) and its receptor (uPAR), GSK-3β and their role in cancer and fibrosis.
Paul Lytle | CFO
Mr. Lytle brings over 30 years of finance and accounting experience, over 25 years of public company experience for Nasdaq listed companies, and over 25 years of biotechnology experience primarily focused on the development and manufacturing of immunotherapies for the treatment of cancer. Mr. Lytle’s biotechnology career started with Avid Bioservices, Inc. (Nasdaq: CDMO) (f/k/a Peregrine Pharmaceuticals, Inc.) from 1997 to 2018, where he raised in excess of $500 million in net proceeds from various equity and debt offerings, including an initial public offering of convertible notes, while serving as Chief Financial Officer for over 18 years. Mr. Lytle was also instrumental in the formation of a successful biologics manufacturing business utilizing excess manufacturing capacity at Avid.
Mr. Lytle is a co-founder of Thendor Therapeutics, LLC, a private biopharmaceutical company, and he has served as its Chief Financial Officer since September 2023. Mr. Lytle is also the co-founder of Mosaic ImmunoEngineering, Inc., a public development-stage biotechnology company, and he has served on its board of directors and as its Executive Vice President, Chief Financial Officer since August 2020. Previously, Mr. Lytle served as Executive Vice President, Chief Financial Officer of Breathe Technologies, Inc., a private medical device company, from September 2018 to December 2019 where he and the team successfully navigated the acquisition by Hillrom Holdings
Sources
- https://actuatetherapeutics.com/team_category/leadership/
- https://finance.yahoo.com/news/actuate-therapeutics-receives-ema-orphan-130000367.html
- https://actuatetherapeutics.com/
- https://actuatetherapeutics.com/our-science/
- https://actuatetherapeutics.com/pipeline/
- https://actuatetherapeutics.com/clinical-trials/
- https://finance.yahoo.com/quote/ACTU/news/
Disclaimer
Disclaimer
Stock Research Today is a project of Virtus Media Group LLC and intended solely for entertainment and informational purposes. This website / media webpage is owned, operated and edited by Virtus Media LLC. Any wording found on this website / media webpage or disclaimer referencing “I” or “we” or “our” or “Virtus Media” refers to Virtus Media LLC. This website / media webpage is a paid advertisement, not a recommendation nor an offer to buy or sell securities. By reading our website / media webpage you agree to the terms of this disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investment or brokerage advice or anything of an advisory or consultancy nature and therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment and educational purposes only. At most, this communication should serve as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. Consult your financial, investment and tax advisors to determine what financial and tax strategies may be right for you. Investor protection and other important information is available at https://www.sec.gov/.
By using our service, you agree not to hold our site, its editors, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within or referred to from our website / media webpage. We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Never invest purely based on our alerts. Gains mentioned in our website / media webpage may be based on end-of-day or intraday data.
This publication and its owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. That information is only valid at the time it is published, and we do not undertake to update it.
Virtus Media’s business model is to receive financial compensation to promote public companies and to conduct investor relations advertising, marketing and publicly disseminate information, not limited to our websites, email, sms, push notifications, influencers, social media postings, ticker tags, press releases, online interviews, podcasts, videos, audio ads, banner ads, native ads, and responsive ads. This compensation is a major conflict of interest in our ability to be unbiased regarding the subject of our reports and communications. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the parties who hired us, or of the profiled companies. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts.
The third parties paying for our services, the profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to impact share prices, possibly significantly. Frequently companies profiled in our alerts experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases.
We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, Virtus Media often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors.
Compensation: Pursuant to an agreement between Virtus Media LLC and Lifewater Media, Virtus Media LLC has been hired by Lifewater Media for a period beginning on 2023-05-16 and ending 2023-05-18 to publicly disseminate information about OTC: IMRFF via digital communications. We have been paid five thousand dollars USD.
